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In two long term studies of non-Hodgkin’s Lymphoma (NHL), the only clinical 
feature associated with a high relapse rate and treatment resistance is the 
presence of the B-cell lymphoma/leukemia-2(bcl-2) proto-oncogene in an over-
active state. Regulation of this gene has shown promise as a means for better 
treatment in patients with relapsed NHL. At MU, in the past, many antisense 
and nonsense peptide-peptide nucleic acid (PNA) conjugates that target the 
bcl-2 proto-oncogene were synthesized and radiolabeled for mRNA binding 
evaluations.  
 
This summer, we synthesized two new peptide-peptide nucleic acid conjugates. 
The first of these was a nonsense sequence of PNA monomers attached to the 
peptide Tyrosine-3-Octreotate (1), and the second was the anti-bcl-2 sequence 
attached to Alanine-box Octreotate (2). The PNA sequences attached to the 
peptides correspond to the first fourteen bases of the bcl-2 proto-oncogene 
(ccagcgtgcgccat) in the case of the anti-bcl-2 compound (2) and correspond to 
no matching sequence in the human genome in the case of the nonsense sequence 
(1). They are both for later use as a negative control in mRNA binding 
evaluations (the previously synthesized positive agent being anti-bcl-2 
attached to Tyrosine-3-Octreotate). The peptides were synthesized using 
standard Fmoc solid phase peptide synthesis on a resin using a very low 
substitution level. The peptides were synthesized in an automatic peptide 
synthesizer, and then elongated with the addition of the PNA monomers 
manually in a reaction vessel. Each peptide-PNA construct was then coupled to 
DOTA (1, 4, 7, 10-tetraazacyclododecane-N, N’, N’’, N’’’-tetraacetic acid), a 
ligand to provide a site for subsequent radiometal chelation. The correct 
molecular weight with a high purity was observed in the LC-MS results for the 
peptide-PNA compound 1 after two attempts, and compound 2 was successful 
after the first attempt. The amount of each construct synthesized should be 
enough for the later mRNA binding study. 
